EFFECTIVENESS AND SAFETY OF SWITCHING TO TENOFOVIR ALAFENAMIDE FUMARATE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B VIRUS INFECTED PATIENTS WITH OSTEOPOROSIS RISK: 24 WEEKS AND 48weeks RESULTS OF A REAL-WORLD STUDY